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 Summary statement.  
Dissection of the impact of AMPK and autophagy on tau-mediated toxicity by using an in 
vivo Drosophila tool as readout to perform preliminary drug screening supported by 
quantitative analyses. 
 
Abstract.    
Neurodegenerative tauopathies are characterized by accumulation of hyperphosphorylated tau 
aggregates primarily degraded by autophagy.  
The 5'AMP-activated protein kinase (AMPK) is expressed in most cells, including neurons. 
Alongside its metabolic functions, it is also known to be activated in Alzheimer’s brains, 
phosphorylate tau and be a critical autophagy activator. Whether it plays a neurotoxic or 
neuroprotective role remains unclear. Complexly in tauopathies, while stress conditions can 
result in AMPK activation enhancing tau-mediated toxicity, AMPK activation is not always 
concomitant with autophagic induction.  
Using a Drosophila in vivo quantitative approach, we have analysed the impact of AMPK 
and autophagy on tau-mediated toxicity, recapitulating the AMPK-mediated tauopathy 
condition: increased tau phosphorylation, without corresponding autophagy activation. 
We have demonstrated that AMPK, binding to and phosphorylating tau at Ser-262, a site 
reported to facilitate soluble tau accumulation, affects its degradation. This phosphorylation 
results in exacerbation of tau toxicity and is ameliorated via rapamycin-induced autophagy 
stimulation.  
Our findings support the development of combinatorial therapies effective at reducing tau 
toxicity targeting tau phosphorylation and AMPK-independent autophagic induction. The 
proposed in vivo tool represents an ideal readout to perform preliminary screening for drugs 
promoting this process. 
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 Introduction. 
The microtubule (MT)-associated protein tau regulates assembly and stability of MTs (Lee et 
al., 2001). In physiological conditions, tau is in a dynamic equilibrium, on and off the MTs. 
Under pathological conditions, this equilibrium is perturbed, resulting in an abnormal 
increase in the aggregation-prone unbound tau fraction.  
The tau MT-binding ability is strongly dependent on tau phosphorylation status (Ballatore et 
al., 2007). Several tau kinases have been identified (Hanger et al., 2009) including  AMPK 
(Thornton et al., 2011), a heterotrimeric Ser/Thr protein kinase complex  composed of three 
highly conserved subunits: the catalytic α subunit (α1 or α2) and two regulatory subunits (one 
each of β1 or β2 and γ1-3) (Carling, 2004).  
First identified as a sensor of energy status able to maintain cellular energy homeostasis 
(Hardie, 2011a; Poels et al., 2009), AMPK is essential for cellular survival in most 
mammalian cells including neurons (Metcalf et al., 2012). In the brain, AMPK activity is 
increased during energy stress (Berger et al., 2006; Gadalla et al., 2004). However, activated 
AMPK (p-AMPK) is abnormally accumulated in tauopathies: neurodegenerative diseases 
associated with the pathological aggregation of tau (Vingtdeux et al., 2011). Indeed, 
previously instances of AMPK activation have been reported to be detrimental to neuronal 
survival, suggesting that inhibition, rather than activation, of AMPK might be 
neuroprotective (McCullough et al., 2005). For example, it has been shown that 
downregulation of AMPK activity is beneficial in both in vitro and in vivo models of familial 
amyotrophic lateral sclerosis, as well as in an in vivo mutant TDP-43 model of motor neuron 
disease (Lim et al., 2012). In addition, recent studies implicate AMPK activity in the 
pathogenesis of Alzheimer’s disease (AD) as a regulator of both tau phosphorylation and 
amyloidogenesis (Thornton et al., 2011; Vingtdeux et al., 2011) More recently Domise et al. 
(Domise et al., 2016), assessed the contribution of AMPKα2 activation in an in vivo model 
(mouse primary neurons) where they reported an increase of tau phosphorylation at multiple 
sites, whereas AMPK inhibition led to a rapid decrease of tau phosphorylation. Furthermore, 
in a mouse model of AD it has been demonstrated that AMPK mediates the synaptotoxic 
effects of Aβ42 oligomers via phosphorylating tau at Ser-262 (Guthrie et al., 2011), leading 
to spine loss in both hippocampal and cortical neurons. Interestingly, Ser-262 is a key residue 
required for tau-MT binding  (Tseng et al., 2008) and, when phosphorylated, a mediator of 
tau toxicity in a transgenic Drosophila model of AD (Iijima et al., 2010). Several studies have 
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 suggested that AMPK is also required for macroautophagy (hereafter referred to as 
autophagy). Autophagy is a process in eukaryotic cells in which regions of cytoplasm, 
insoluble protein aggregates, damaged mitochondria, or invading pathogens are engulfed by a 
double membrane to form vesicles, fusing with lysosomes to degrade the contents (Hardie, 
2011b). 
AMPK mediates autophagy activation directly by phosphorylation of the protein kinase that 
initiates autophagy, ULK1 (Egan et al., 2011; Kim et al., 2011) and indirectly, through 
inactivation of the mTOR complex-1 by phosphorylating both TSC2 (Inoki et al., 2003) and 
Raptor (Hardie, 2008). 
A decrease in autophagic activity has been linked to several neurodegenerative disorders 
associated with the accumulation of misfolded protein aggregates, while increased autophagy 
has been shown to facilitate the clearance of aggregation-prone proteins and promote 
neuronal survival in mouse and fly models of tauopathies (Berger et al., 2006; Caccamo et 
al., 2010; Majumder et al., 2011; Rodriguez-Navarro et al., 2010).  
The apparent separate roles of AMPK in both promoting tau phosphorylation and regulating 
autophagy are therefore important to analyse.  They will inform how any future potential 
AMPK directed pharmacological interventions might succeed. 
In the present study, we have attempted to identify the cascade of events mediated by AMPK 
that affect tau-induced toxicity using both an intact mammalian cell line and an in vivo 
Drosophila model of tauopathy. Drosophila has been widely used as an in vivo model for 
tauopathies, reiterating many features of the mechanisms underlying human tau-induced 
neurodegenerative disease, in particular the roles of solubility and phosphorylation 
(Gistelinck et al., 2012). The Drosophila compound eye, allowing easy access, represents the 
most commonly used read-out to evaluate toxicity of neurodegenerative proteins, including 
tau. Indeed, targeted expression of either wild-type or mutant tau in the retina caused 
alterations in external eye structures, characterized by size reduction and rough appearance 
(Prussing et al., 2013). The Drosophila eye tauopathy model thus constitutes a genetically 
sensitized system that allows the identification of modifier mechanisms by assessing its 
roughening as a quantitative readout of neurotoxicity (Caudron et al 2014). Additionally, 
Drosophila has proven to be also a powerful multicellular model for genetic and 
pharmacological manipulation of autophagy (Nezis, 2012).  
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 Here we report an in vitro physical interaction of tau with AMPK and with active AMPK (p-
AMPK), and we demonstrate how AMPK modulation affects the phospho-status and stability 
of tau.  Furthermore, in vivo, by overexpressing an AMPK constitutively active (AMPKα1-
CA) mutation, we exacerbate tau toxicity by increasing tau phosphorylation without 
corresponding autophagy activation. Interestingly, treatment with the autophagy activator 
rapamycin was able to rescue the additional toxicity.   
Our findings support the development of new therapies targeting tau clearance via AMPK-
independent autophagic induction.  
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 Results. 
Tau and AMPK physically interact in vitro in intact mammalian cells. 
It has been demonstrated that activated AMPK phosphorylated at Thr-172 (p-AMPK) is 
abnormally accumulated in all the major tauopathies, including AD (Vingtdeux et al., 2011). 
To determine if AMPK and tau are able to physically interact, we chose a simple mammalian 
cell line model (HEK293T cells). This cell line does not express tau (Guthrie et al., 2011) and 
has been previously used to study AMPK regulated events, including autophagy (Kim et al., 
2011). Additionally, it has recently been proposed as a non-neuronal cell model where tau 
pathology can be studied in a stable, viable and easily transfected human cell line (Houck et 
al., 2016). N-terminal-FLAG-tagged tau was transfected into HEK293T cells and 
immunoprecipitation of tau was performed with anti-FLAG antibody. Detection of co-
immunoprecipitating species was performed by western blotting with an anti-AMPKα 
antibody. Tau was found to co-immunoprecipitate with endogenous AMPKα (Fig.1A). 
Further validation for AMPK/tau interaction was provided by immunoprecipitating 
endogenous AMPK with an anti-AMPKα antibody, whilst detecting the co-
immunoprecipitating species with an anti-tau antibody (Fig.1B). Similarly, by 
immunoprecipitating with an anti-phospho antibody against AMPKα (p-AMPKα) we found 
that tau also physically interacts with active AMPKα (Fig.1C).  
 
AMPKα1 affects exogenous tau stability in vitro. 
It has previously been demonstrated that AMPK can phosphorylate tau at Ser 262 in a cell 
free in vitro assay (Vingtdeux et al., 2011), as well as by reintroducing the AMPK upstream 
activator LKB1 in to HeLa cells (Guthrie et al., 2011). We now wished to determine the 
consequence of AMPK activity on tau phospho-status in our HEK293T intact cell model. To 
evaluate the effect of AMPK overactivaction on tau, we used a constitutively-active form of 
AMPKα1 (myc-tagged AMPKα1-CA). Alternatively, to evaluate the effect of reduced 
AMPK activity on tau, we used a kinase-dead (K45R) variant of the AMPKα1 subunit 
(AMPKα1-KD), previously demonstrated to act as a dominant-negative inhibitor of 
endogenous AMPK (Crute et al., 1998). As reported in COS7 cell lines (Crute et al., 1998), 
transfection of AMPKα1-KD in to HEK293T cells led to a significant degradation of 
endogenous AMPK protein (Suppl. 1A, quantification Suppl. 1B).   
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 Knockdown of endogenous AMPK via AMPKα1-KD overexpression caused dramatic 
reductions in total tau soluble fraction levels (an 80% reduction, Fig.2A, lanes 5-6, 
quantification Fig.2B) compared to AMPKα1-CA-transfected cells (Fig.2A, lanes 1-2), with 
a concomitant loss of some tau species. 
In an attempt to identify the phosphorylation status of the different tau species detected, we 
co-transfected AMPKα1-CA and FLAG-tagged tau S262A. Western blots of cells transfected 
with this mutant tau (Fig.2A, lanes 3-4) revealed that it migrated differently to the wild-type 
tau. Tau S262A protein displayed, as expected for a non-phosphorylatable mutant, a distinct 
migration pattern characterised by a faster mobility compared with the wild-type tau (Fig.2A, 
lanes 1-2). In particular, the tau S262A migration pattern allowed us, by comparison with the 
wild-type tau migration pattern, to identify and quantify (Fig.2C) the tau species 
phosphorylated at Ser-262. Interestingly, the lost species in AMPKα1-KD-transfected cells 
correspond to the Ser-262 phosphorylated species (Fig.2A, lanes 5-6). Thus, the genetic 
inactivation of endogenous AMPK, via AMPKα1-KD, results in a lack of Ser-262 
phosphorylated tau, as well as the loss of other species yet unidentified. This suggests that 
under normal conditions, the phosphorylation of tau by AMPK is an important determinant of 
tau stability and that Ser-262 is one of the sites involved in this process.  
 
AMPK interacts with tau in vivo. 
In vivo interactions between human tau and Drosophila AMPK. 
While HEK293T cells have been useful to determine the biochemical interactions of AMPK 
and tau within an intact cellular system, they are not representative of either neurons or an in 
vivo situation. Drosophila melanogaster models of tau toxicity have been widely used to 
investigate interactions. Using the binary system UAS-GAL4 (Brand and Perrimon, 1993), it 
has been shown that misexpression of wild-type human tau in the fly, under the control of the 
retina-specific glass multiple repeat enhancer  GMR (Freeman, 1996),  caused a moderate 
rough eye phenotype (Wittmann et al., 2001). The tau-induced phenotype thus provides an 
excellent readout with which to assay tau toxicity (Jackson et al., 2002). In order to 
investigate whether AMPKα is a mediator of tau-dependent toxicity, we genetically 
downregulated endogenous Drosophila AMPKα using RNA interference (RNAi dAMPKα) 
under the control of the retina-specific GMR driver. The presence of the hemizygous GMR 
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 driver (Fig.3A) or the expression of RNAi dAMPKα (data not shown) caused no appreciable 
visible external phenotype, indicating that expression of RNAi AMPKα is not detrimental to 
the Drosophila eye.  Co-expression of tau and RNAi dAMPKα (GMR/+; tau/ RNAi 
dAMPKα) partially rescued the tau-induced eye phenotype as determined by scanning 
electron microscopy (Fig.3A). 
To provide a quantitative evaluation of the eye phenotype, we used a statistical procedure, 
Quantitative Edge Detection (QED), for the assessment of ommatidial distortion in terms of 
deviation from ommatidial roundness caused by transgenic manipulations of the eye 
(Caudron et al., 2014). The distortion coefficient (DC) ranges from 0 for no distortion to 1 for 
maximal distortion.  Comparison of scanning electron microscope (SEM) images from 
GMR/+ and GMR/tau-expressing eyes showed that the distribution of ommatidial distortion 
was significantly different between the two, as quantified by the mean DC values (± standard 
deviation) (0.201 ± 0.015, n = 15 and 0.409 ± 0.070, n = 15 respectively; Fig.3B green and 
black line respectively).  QED analysis confirmed the reduced severity of the GMR/tau/ 
RNAi dAMPK genotype compared with the GMR/tau alone, seen upon visual examination of 
the SEMs, via a leftward shift in the cumulative distribution of DC: (mean DC = 0.317 ± 
0.037, n = 25; respectively, Fig.3B orange line).  
 
AMPK enhances tau neurotoxicity in a Drosophila model.  
In order to recapitulate the human AMPK/tau pathway in our in vivo Drosophila model, we 
co-expressed human tau with the relevant human AMPKα1 mutants previously characterised 
in vitro and assayed the resultant toxicity. Several insertion lines for both transgenes were 
used for the initial experiments; the results for two lines of the human AMPKα1-CA 
transgene (hereafter AMPKα1-CA) and three lines of the human AMPKα1-KD transgene 
(hereafter AMPKα1-KD) were used for initial SEM analyses and similar results were 
obtained for each transgene (data not shown). The overexpression of the AMPKα1 transgenes 
under the control of the GMR-GAL4 driver in the resulting AMPKα1-CA and AMPKα1-KD 
lines where validated by western blot (Suppl. 3A-B). The overexpression of those transgenes 
caused no appreciable external eye phenotype (Suppl. 4 A-B).  
Co-expression of tau and AMPKα1-CA (GMR/+; tau/AMPKα1-CA) caused an exacerbation 
of the toxic tau eye phenotype (Fig.4A). By using QED, we found a significant shift to the 
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 right of the DC distribution and an increase in the mean DC when compared to both control 
and tau alone (0.488 ± 0.073, n = 10; Fig.4B, blue line).  
In contrast, co-expression of tau and AMPKα1-KD (GMR/+; tau/AMPKα1-KD) ameliorated 
the basal tau phenotype. Quantitative analysis using QED validated the SEM analyses (mean 
DC = 0.314 ± 0.018, n = 12) and the rescue resulted in a shift to the left of the DC 
distribution compared with tau alone (Fig.4B, respectively red line and black line). These 
data are consistent with the hypothesis that AMPK activation can promote tau toxicity in this 
model.    
  
AMPKα1 overactivation promotes exogenous tau phosphorylation in vivo. 
Phosphorylation of tau protein characterises human tauopathy disorders. To address whether 
AMPK overactivation-induced changes in tau toxicity coincide with changes in tau 
phosphorylation, we analysed tau phosphorylation in tau/AMPKα1-CA flies. Western blots 
analyses of fly head extracts in tau/AMPKα1-CA-expressing flies showed that AMPK plays 
an important role in the phosphorylation of tau: increased AMPK activity drives tau 
phosphorylation in the fly, as shown in Fig.5A, where samples were probed with antibody 
against total tau (upper panel), against p262 (middle panel) and against actin (lower panel) 
and quantified (Fig.5B).  This analysis revealed that tau in tau/AMPKα1-CA flies is strongly 
phosphorylated in comparison to the flies expressing tau alone (Fig.5B).    
Probing our samples with antibodies against total or phospho tau, we observed that tau 
protein runs with a specific electrophoretic profile, characterised by a strong ~60 kDa band 
and an additional lower band (~55kDa). Previous work has shown that pathologically 
hyperphosphorylated (including pSer-262) human tau band runs at ~60 kDa, whereas the 
normally phosphorylated tau runs in the range of 55–60kDa (Ali et al., 2012; Le Corre et al., 
2006). Consistent with this observation, AMPK overactivation caused an increased in the 
immunoreactivity for the pathologically hyperphosphorylated species, as showed in Fig.5C 
where we quantified the immunoreactivity for p262 of the upper mobility band. 
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AMPKα downregulation destabilizes pathological tau species and changes tau 
phosphorylation pattern.   
To address whether the reduced tau toxicity associated with AMPK downregulation (Fig.4B) 
coincides with changes in tau protein phosphorylation, we analysed tau protein in both 
tau/dAMPK RNAi and tau/AMPKα1-KD flies. Analysis of western blots showed that, as in 
HEK293T, AMPK plays an important role in the stability of tau as downregulation of AMPK 
activity, both via RNAi and AMPKα1-KD, drives tau protein destabilization (Fig.5D). 
Interestingly, AMPK downregulation caused a shift to the higher mobility band and a 
reduction in the immunoreactivity for the pathologically hyperphosphorylated species, as 
showed in Fig.5E where we quantified the reduction of the slower mobility upper band.  
Probing our samples with an antibody against tau phosphorylated on Ser-262 (p262), we 
validated that the pathologically hyperphosphorylated band consists of tau 
hyperphosphorylated at Ser-262 and the immunoreactivity for that band is reduced by AMPK 
downregulation (Fig.5F-G). This is again supportive of a link between AMPK 
downregulation and neuroprotection. 
 
The catalytic subunit of AMPK influences autophagy in the Drosophila eye.  
It has been demonstrated that Ref(2)P, the homologue of mammalian p62, is a major 
component of protein aggregates formed during normal aging in the adult fly brain.  It also 
accumulates in protein aggregates in flies that are defective in autophagy and in models of 
human neurodegenerative diseases (Nezis et al., 2008). Accordingly increases in Ref(2)P are 
interpreted as reflecting dysfunctional autophagy.  
Given AMPK’s known roles in autophagy activation, we sought to test the autophagy status 
in our transgenic fly models. We therefore assayed Ref(2)P accumulation in tau, 
tau/AMPKα1-CA and tau/AMPKα1-KD flies head extracts.   
In our model, we detected no changes in Ref(2)P accumulation in tau/AMPKα1-CA 
compared to tau alone (Fig.6A, quantification Fig.6B), demonstrating that overexpression of 
AMPKα1-CA, which caused an exacerbation of tau-dependent toxicity, did not affect 
autophagy activation. In contrast, Ref(2)P accumulated in tau/AMPKα1-KD flies (Fig.6A-B) 
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 compared to tau alone. This suggests that the down regulation of endogenous AMPK impairs 
autophagy.  
 
Pharmacological activation of autophagy by rapamycin decreases AMPKα1-CA tau-
mediated toxicity. 
In order to test whether induction of autophagy downstream of AMPKα1-CA was beneficial 
in AMPKα1-CA -mediated tau-dependent toxicity, we fed rapamycin to flies co-expressing 
tau and human AMPKα1-CA (tau/AMPKα1-CA) and analysed the eye phenotypes. Whereas 
0.1 µM rapamycin had no effect (data not shown), 1 µM treatment ameliorated the tau 
AMPKα1-CA mediated exacerbation of the toxic tau eye phenotype, compared with the same 
genotype fed with DMSO (Fig.6C). QED quantitative analysis validated the SEM analyses 
(DC = 0.64± 0.10, n = 9 for DMSO control flies versus 0.51± 0.11, n = 7 for rapamycin 
treated flies) and the rescue resulted in a clear shift to the left of the DC distribution 
compared with DMSO treated flies (Fig.6D, respectively black line and red line). 
Collectively, these data are consistent with the hypothesis that induction of autophagy 
downstream of AMPK-mediated tau phosphorylation is beneficial in reducing tau-dependent 
neurodegeneration. 
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 Discussion 
The exact role of AMPK in neurodegeneration is still highly controversial. It has been 
reported that a beneficial outcome of AMPK activation is to promote neuronal maintenance 
under normal conditions and upon metabolic stress.  Studies in Drosophila have strengthened 
this notion demonstrating that AMPK deficiency causes neurodegeneration (Poels et al., 
2009; Ronnett et al., 2009). 
However, AMPK activation has also been found to be detrimental to neuronal survival (Li et 
al., 2006; McCullough et al., 2005). Downregulation of AMPK has been reported to be 
beneficial in models of familial amyotrophic lateral sclerosis, as well as in an in vivo model 
of motor neuron disease (Lim et al., 2012). In addition, recent studies implicate AMPK 
activity in the pathogenesis of AD as a regulator of both tau phosphorylation and 
amyloidogenesis (Thornton et al., 2011; Vingtdeux et al., 2011) and the contribution of 
AMPKα activation has been assessed in mouse primary neurons, where it has been reported 
an increase of tau phosphorylation at multiple sites upon endogenous AMPK activation, 
whereas AMPK inhibition led to a rapid decrease of tau phosphorylation (Domise et al., 
2016). 
Among its different roles, AMPK activates autophagy (Egan et al., 2011; Hardie, 2008; Inoki 
et al., 2003; Kim et al., 2011), the main pathway for eukaryotic cells to degrade organelles 
and long-lived proteins (Jaeger and Wyss-Coray, 2009).  Interestingly, defective autophagy 
has also been implicated in the pathogenesis of several major neurodegenerative diseases, 
particularly AD (Nixon and Yang, 2011). Additionally, defects in autophagy lead to an 
increased accumulation of tau phosphorylated at the KXGS motifs (Wang et al., 2009), such 
as Ser-262, species reported to be also less susceptible to proteasomal degradation mediated 
by Hsp90 (Dickey et al., 2006; Dickey et al., 2007). 
In the present study, we assessed in a Drosophila in vivo model the contribution of AMPK 
modulation to tau-mediated toxicity.  
We initially established whether AMPK physically interacts with tau in intact HEK293T 
cells. Using immunoprecipitation, we found that AMPK can interact with tau (Fig.1A, B) as 
can the active form of AMPK (Fig.1C). Attempting to define the simplest and most effective 
way to increase AMPK activity, we took advantage of the AMPKα1-CA mutation. This 
mutation frees the catalytic α-subunit from its regulatory β and γ subunits (Woods et al., 
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 2000) rendering it constitutively active. Using a Drosophila model expressing human tau in 
the developing fly eye we examined in vivo the effect of AMPKα1-CA on tau toxicity. In 
these flies we exacerbated tau toxicity as determined by analysis of ommatidial distortion 
(Fig.4). Comparative analysis of protein lysates from flies overexpressing tau±AMPKα1-CA 
showed that co-expression of AMPKα1-CA significantly elevated the immunoreactivity of 
pSer-262 (Fig.5A).   
Previously, in a cell free in vitro assay, AMPK has been demonstrated to phosphorylate tau at 
Ser-262 (Vingtdeux et al., 2011). Phosphorylation at Ser-262 is significantly elevated in 
human AD pre- and intra-neuronal tangles (Augustinack et al., 2002). Consequently, 
phosphorylation of tau at Ser-262 by AMPK may represent an important event in the early 
stages of AD pathogenesis.  
It has been proposed that tau phosphorylated at such KXGS motifs, is likely to be resistant to 
proteasomal degradation (Dickey et al., 2006; Dickey et al., 2007) and to accumulate when 
autophagy is defective (Wang et al., 2009). Indeed in some of our lines, we found that 
AMPKα1-CA overexpression resulted in increased exogenous tau stability (data not shown).  
We have also demonstrated that downregulating AMPK activity affects tau, both in vitro and 
in vivo models. In fact, we established that when endogenous AMPK activity is decreased 
using dominant negative AMPKα1-KD in HEK293T cells, soluble tau levels also decrease. 
This relationship was particularly evident in pathologically phosphorylated species (Fig.2A, 
lane 5-6, Fig.2B). In the fly, we downregulated dAMPK by using two independent means: 
dAMPK-RNAi-mediated silencing and by overexpressing the human AMPKα1-KD.  In both 
cases, by reducing endogenous dAMPK, we reduced the tau-induced toxicity (Fig.3-4).   
Particularly, the diminished tau toxicity is likely due to a reduction in both tau 
phosphorylation and stability: lowering AMPK in vitro via expression of AMPKα1-KD 
altered the phosphorylation profile of tau and led to compromised soluble tau stability in cells 
(Fig.2). In vivo, analysis of protein lysates from flies expressing tau (Fig.5) revealed the 
presence of a distinct doublet, with one band having a higher electrophoretic mobility. This 
indicates the presence of a population of tau species at a different phosphorylation status, 
which results in different electrophoretic migration.  
It has been proposed (Ali et al., 2012; Le Corre et al., 2006) that pathologically 
hyperphosphorylated (including pSer-262) human tau bands run at 64 kDa, whereas the 
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 normally phosphorylated tau runs in the range of 55–60 kDa. Interestingly, in tau±RNAi 
dAMPK or AMPKα1-KD flies we observed how the reduction of AMPK activity affects the 
levels and distribution of tau proteins (Fig.5 D, F). Specifically, reduced AMPK levels 
decreased the overall levels of pathological tau high molecular species, resulting in a band 
shift in the migration of total (Fig.5D) and pSer-262 (Fig.5F) tau species. In addition, the 
marginal but still detectable immunoreactivity of pathological tau high molecular weight 
species phosphorylated at Ser-262 is a clear indication that Ser-262 is not the only site 
phosphorylated in the pathological tau and the remaining immunoreactivity could be 
responsible for the residual toxicity in tau±RNAi dAMPK or AMPKα1-KD flies eyes. 
Our data are consistent with a detrimental effect of AMPK overactivation on tau-mediated 
toxicity. In our AMPK overactivation model we detected more toxic hyperphosphorylated 
tau. On the other hand, AMPK downregulation, preventing tau phosphorylation, destabilised 
the pathological tau species and rescued the tau toxic eye phenotype in the fly.  
How might this be explained with the observations of the direct (Egan et al., 2011; Kim et al., 
2011) and indirect (Hardie, 2008; Hardie, 2011b) activation of autophagy by AMPK and the 
attenuated tauopathy reported in different models after autophagy induction (Congdon et al., 
2012; Schaeffer et al., 2012)?   
To attempt to answer this question we measured the levels of accumulation of Ref(2)P, the 
Drosophila orthologue of p62, a component of protein aggregates in flies defective in 
autophagy and models of human neurodegenerative diseases, in which it strongly 
accumulates (Nezis et al., 2008). This approach allowed us to assess in our different 
experimental conditions the level of AMPK-mediated autophagy activation and to correlate 
that with the tau toxicity. As schematised in Fig.7, our data demonstrates that downregulation 
of AMPK via AMPKα1-KD showed an accumulation of Ref(2)P (Fig.6). This is indicative of 
a reduction in autophagic flux, consistent with defective autophagy, as expected from 
mammalian models, where the expression of a dominant-negative form of AMPK completely 
inhibited autophagic proteolysis in HT-29 and HeLa cells (Meley et al., 2006). From the 
work presented here our model demonstrates that in AMPKα1-KD-tau flies, tau does not 
accumulate. Such flies do not need the beneficial effect of autophagy induction since they are 
likely to be able to clear tau via other degradative pathways. Consequently the AMPK-
mediated autophagy downregulation does not affect the tau-phenotype. 
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 Conversely, the increase in tau toxicity provoked by AMPKα1-CA is due to the increased 
phosphorylation and possible reduced degradation of tau, concomitant with the inability of 
AMPKα1-CA to effectively induce autophagy. Indeed, the lack of increased autophagic 
induction by AMPKα1-CA has been previously demonstrated in HT-29 and HeLa 
mammalian cells (Meley et al., 2006).  
Eventually, the reduction in tau toxicity found in AMPKα1-CA-tau flies treated with 
rapamycin (Fig.6C-D), is consistent with the beneficial outcome in autophagy induction 
downstream of AMPK.  
The Drosophila model presented in this paper demonstrates an ability to affect tau toxicity 
via AMPK-modulation in vivo. 
In human tauopathies, stress conditions result in AMPK overactivation and increased kinase 
activity, responsible for tau phosphorylation. Additionally, AD patients are known to be 
defective in autophagy activation (Salminen et al., 2011). Our AMPKα1-CA-tau model 
recapitulates this disease process by increasing tau phosphorylation, in particular at Ser-262, 
without corresponding autophagy activation. This site is reported to promote resistance to 
degradation (Dickey et al., 2006; Dickey et al., 2007), leading to tau accumulation that 
requires autophagy for clearance.  
While AMPK is potentially able to offer protective effects through regulation of autophagy 
(Egan et al., 2011; Hardie, 2008; Hardie, 2011a; Kim et al., 2011), given the resulting 
increased phospho-tau levels as observed from the detrimental effects seen here in vivo for 
AMPK-CA, we propose that this results on balance in toxic accumulation of phospho-
tau. Accordingly, our results indicate that pharmacological induction of autophagy 
downstream of AMPK may be beneficial in tau-dependent neurodegeneration.  
Taken together our findings raise the possibility that new therapies targeted at AMPK-
mediated tau phosphorylation might be effective at reducing tau toxicity. The potential for 
such treatments to compromise autophagy are likely to be outweighed by the benefits 
associated with reducing phospho-tau toxicity. This opens the possibility of combinatorial 
therapy with treatments targeted at AMPK-independent autophagic induction to promote tau 
clearance. The Drosophila model presented here offers an opportunity to test the 
development of such drugs. 
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 Materials and Methods. 
Cell lines and transfection. HEK293T cells were maintained in DMEM of high glucose, 
supplemented with 10% FBS and grown at 37°C in a humidified atmosphere with 5% CO2.  
Transfections were performed using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s protocol with empty pCMV-FLAG, pCMV-FLAG-tau (kind gifts of Dr. 
Calum Sutherland, University of Dundee), pCMV-FLAG-S262A tau or pCMV-FLAG-
T231A tau plasmids in combination with empty pcDNA3 (Invitrogen), pcDNA3 N-terminal-
Myc-AMPKα1-CA (kind gift of Prof. David Carling, MRC Clinical Sciences Centre, 
Imperial College, London). pCMV-FLAG-tau is an N-terminal Flag tagged human 
microtubule-associated protein tau isoform 2, Genbank NP_005901.2, cloned into the pCMV 
FLAG-vector. pCMV-Myc Tag3b AMPKα1-KD and pCMV-FLAG-S262A tau were 
obtained by site-directed mutagenesis respectively on pCMV-Myc Tag3b AMPKα1-wt and  
pCMV-FLAG-tau, via site-directed mutagenesis using a QuikChange site-directed 
mutagenesis kit (Stratagene). 
Fly stocks. The transgenic fly line carrying the human 0N4R tau, with the four tubulin-
binding domains (R) at the C-terminal region and no N-terminal insert (N), was a kind gift 
from Dr. Mel Feany (Harvard Medical School, (Wittmann et al., 2001).  UAS-AMPKα1-CA 
and UAS- AMPKα1-KD transgenic lines were obtained by directional cloning of cDNAs, 
into the Drosophila expression vector, pUAST. Transgenic flies were produced by BestGene 
Inc using standard procedures. UAS-AMPK RNAi flies were obtained from the VDRC 
(Vienna Drosophila RNAi Center, Transformant ID 106200). All other fly stocks were 
obtained from the Bloomington Drosophila Stock Center (Indiana University). Crosses were 
maintained on standard cornmeal-based Drosophila medium at 25°C. 
Immunoprecipitation and immunoblotting. HEK293T cells were recovered by gentle 
pipetting in PBS1X, centrifuged at 5000 g for 5 min in a microfuge and resuspended in 0.5 
mL lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 
mM Sodium Orthovanadate, 50 mM Sodium Fluoride, and Complete protease inhibitor 
tablets (Roche). After sonication for 15 min and incubation on ice for 10 min, samples were 
centrifuged at 15700 g for 30 min. The supernatant was recovered and the protein 
concentration determined. Proteins were either directly analysed, after electrophoresis, by 
western blotting (see below) or immunoprecipitated. In the second case, extracts were 
incubated under rotation for 2 h at 4°C with ANTI-FLAG M2 Affinity Gel (Sigma, A2220) 
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 according to manufacturer’s instructions or with the relevant antibody. In the latter case, 
Protein A-Sepharose (Generon) was then added and the mixture incubated for a further 2 h at 
4°C. Sepharose beads were quickly centrifuged in a microfuge (2’ at 8000 rpm) and washed 
three times with lysis buffer. After the final wash, the beads were resuspended in 30 µl 
Laemmli sample buffer, boiled 10min at 90°C and electrophoresed through a 10% acrylamide 
gel. Adult flies were collected, heads dissected and homogenised in a lysis buffer containing 
50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 1 mM Sodium 
Orthovanadate, 50 mM Sodium Fluoride, 5 mM Sodium Pyrophosphate, 0.27 M Sucrose, 
0.1% β-Mercaptoethanol and complete protease inhibitor tablets (Roche). Protein content was 
determined using Bradford reagent (Bio-Rad). Extracts were mixed with SDS sample buffer 
and heated at 90˚C for 10 min before being separated by 10% SDS-PAGE. 
Lysates or immunocomplexes subjected to SDS-PAGE were transferred to nitrocellulose 
membranes (Amersham Biosciences). Nitrocellulose blots were incubated at room 
temperature for 30min in blocking buffer (Tris-buffered saline with 0.1% Tween containing 
5% bovine serum albumin (BSA)and then incubated overnight at 4°C in 5% BSA with the 
recommended concentrations of indicated antibodies. After washing three times for 15 min 
each with Tris-buffered saline containing 0.1% Tween, the blots were incubated with 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Amersham Pharmacia 
Biotechnology), followed by washing. Immunoreactive bands were visualized with enhanced 
chemiluminescence substrate (Pierce, Rockford, IL, U.S.A.). Developed films were scanned 
using a flat-bed scanner and densities of bands were measured using ImageJ software. 
Membranes were immunoblotted with the following antibodies at the indicated dilutions: tau 
T46 (Abcam AB22261, 1:1000), tau phospho S262 (Abcam AB4856, 1:1000), tau phospho 
T231 (Abcam, AB30665, 1:1000), AMPKα (Cell Signaling, #2532, 1:1000), Phospho-
AMPKα (Thr172) (40H9) (Cell Signaling, #2535, 1:1000), anti-FLAG M2 (Sigma, F3165, 
1:5000), Anti-beta Tubulin (Abcam  AB6046, 1:5000), anti-actin (JLA20, Developmental 
Studies Hybridoma, Ames, IA, 1:2000),  anti-Ref(2)P (Wyers et al., 1995) (kind gifts of Dr. 
Ioannis P. Nezis, 1:1,000). 
Scanning electron microscopy (SEM). To analyse external eye structure using SEM, female 
flies were fixed overnight in 4% PFA in PBS1X at 4˚C. Flies were then dehydrated through 
an acetone series (10%, 30%, 50%, 70%, and 90% in H2O), incubating on a rotator in 1 ml of 
solution for 15 mins at room temperature (RT). Flies were transferred to 100% acetone, for at 
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 least 2 days at 4˚C, then attached to stubs using double-sided tape, sputter coated in gold for 
60 seconds and imaged using a Zeiss Supra55 VP SEM at 150X magnification. 
Quantitative edge detection (QED). Software for assessing the level of ommatidial disruption 
in adult fly eyes (QED) was developed in collaboration with the Statistics Department at 
Warwick University (Caudron et al., 2014). For the purpose of this study, only data for the 
roundness measure (termed ommatidial distortion) has been used as it is a more sensitive 
measure, sampling hundreds of times per image as opposed to once per image for the distance 
and angle measures. Raw data from QED was collected and transferred to GraphPad software 
(version 4) in order to produce cumulative plots of ommatidial distortion versus fly count (in 
percent of total). Significance levels were calculated with the Mann-Whitney U test. 
Rapamycin Treatment. Rapamycin (LC Laboratories) was dissolved in DMSO (500μM 
stock) and added to fly food at 0.1μM and 1μM. For control food DMSO alone (0.02% and 
0.2% respectively) was added. 
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 Figures 
 
 
 
Figure 1. Immunopreciptation reveals a physical association between tau and AMPKα. 
(A) Lysates from HEK293T cells transfected with a pCMV–Flag vector (negative control) 
and a pCMV–Flag-tau were immunoprecipitated with ANTI-FLAG M2 Affinity Gel. 
Immunoprecipitates were analysed by western blotting, probing against AMPKα. Uncropped 
blots and input controls are shown in Suppl. Figure 1(A-B). (B) Identical lysates were 
immunoprecipitated with anti AMPKα antibody and then incubated with protein A-
Sepharose. Immunoprecipitates were analysed by western blotting, probing against total tau. 
Control blots are shown in Suppl. Figure 1(C).  (C) Interaction of tau with active AMPK 
(pAMPKα). Identical lysates were immunoprecipitated with anti phospho-AMPKα (Thr172) 
antibody and then incubated with protein A-Sepharose. Immunoprecipitates were analysed by 
western blotting, probing against total tau.  Control blots are shown in Suppl. Figure 1(D). 
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Figure 2.  AMPKα1 affects exogenous tau stability. 
(A) Extracts from HEK293T transfected as indicated were used for detection of flagged-tau 
and phospho-tau, probing with anti-Flag and anti-p262-tau antibodies respectively, and then 
normalized with respect to tubulin. 
(B) Tau stability quantification expressed as a ratio between tau/tubulin is shown in the 
graph. Data are shown as mean ± standard deviation.  8.25 ± 2.2 for tau wt + AMPKα1-CA, 
0.77 ± 0.24 for tau wt + AMPKα1-KD. P values were calculated by one-way ANOVA. 
Asterisks indicate significant differences (P<0.05). ** P< 0.01, n≥3 independent HEK293T 
transfections. 
(C) Quantification of phospho-tau species as a ratio between p262 tau/tubulin is shown in the 
graph. Data are shown as mean ± standard deviation.   0.37 ± 0.03 for tau wt + AMPKα1-CA, 
0.12 ± 0.005 for tau S262A + AMPKα1-CA, 0.11 ± 0.01 for tau wt + AMPKα1-KD. P values 
were calculated by one-way ANOVA. Asterisks indicate significant differences (P<0.05). ** 
P< 0.01, n≥3 independent HEK293T transfections. 
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Figure 3. Downregulation of Drosophila AMPKα (dAMPKα) partially rescued the tau-
induced degenerative eye phenotype. 
(A) Scanning electron microscope (SEM) images of the external eye of control flies 
(GMR/+), flies expressing tau (GMR/+; tau/+) and flies co-expressing tau and RNAi 
dAMPKα (GMR/+; tau/ RNAi dAMPKα) under the control of the GMR-GAL4 driver. Scale 
bar in SEM images is equivalent to 100 µm.  
(B) Quantitative analysis of tau-induced toxicity displayed as the cumulative distribution of 
ommatidial distortion coefficients (DC) obtained via QED analysis for control flies (GMR, 
green line), flies expressing tau (GMR tau, black line) and flies co-expressing tau and RNAi 
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 dAMPKα (GMR tau RNAi dAMPKα, orange line) under the control of the GMR-GAL4 
driver. Co-expression of RNAi dAMPKα with tau reduced tau-induced ommatidial distortion, 
as indicated by the leftward shift of the DC distribution, compared to the distribution of 
ommatidial distortion coefficients for flies expressing tau alone. The SEM images are 
representative of the median DC values for each genotype. The phenotypes associated with 
the lower and upper DC values can be seen in supplementary figure 5.  
GMR n = 14, GMR tau n = 14, GMR tau RNAi dAMPKα n = 25. Levels of significance for 
Mann-Whitney directional tests are ˂0.01 for both the compared groups: GMR versus GMR 
tau and GMR tau versus GMR tau RNAi dAMPKα. 
Validation of dAMPK downregulation upon expression RNAi dAMPKα under the control of 
the GMR-GAL4 driver can be seen in supplementary figure 3(B).  
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Figure 4. Recapitulation of the human AMPK/tau pathway in the Drosophila eye. 
(A) Scanning electron microscope (SEM) images of the external eye of flies expressing tau 
(GMR/+; tau/+) and flies co-expressing tau and human AMPKα1-CA (GMR/+; tau/ 
AMPKα1-CA) or tau and human AMPKα1-KD (GMR/+; tau/ AMPKα1-KD) under the 
control of the GMR-GAL4 driver. Scale bar in SEM images is equivalent to 100 µm.  
(B) Quantitative analysis of tau-induced toxicity as distribution of ommatidial distortion 
coefficients (DC) for  flies expressing tau (GMR tau, black line), flies co-expressing tau and 
AMPKα1-CA (GMR tau+ AMPKα1-CA, blue line), tau and AMPKα1-KD (GMR tau+ 
AMPKα1-KD, red line) under the control of the GMR-GAL4 driver.  
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 The SEM images are representative of the median DC values for each genotype. The 
phenotypes associated with the lower and upper DC values, can be seen in supplementary 
figure 6.   
GMR tau n = 14, GMR tau+ AMPKα1-CA n = 9, GMR tau+ AMPKα1-KD n=12. 
Levels of significance for Mann-Whitney directional tests are ˂0.01 for both the compared 
groups: GMR tau versus GMR tau+ AMPKα1-CA and GMR tau versus GMR tau+ 
AMPKα1-KD. 
Validation of AMPKα1 overexpression in transgenic lines AMPKα1-CA and AMPKα1-KD 
under the control of the GMR-GAL4 driver can be seen in supplementary figure 3(A-B).  
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Figure 5. AMPKα1 modulation affects tau phosphorylation and stability. 
AMPKα1 overactivation promotes tau phosphorylation. 
(A) Extracts of fly heads from flies expressing tau alone and in combination with AMPKα1-
CA probed with total tau or pS262 antibodies and normalized against actin. 
(B) Quantification of tau phosphorylation as a ratio between ptau/total tau is shown in the 
graph. Data are shown as mean ± standard deviation.   0.94 ± 0.14 for tau wt and 1.97 ± 0.21 
for tau+ AMPKα1-CA. P values were calculated by one-way ANOVA. Asterisks indicate 
significant differences (P<0.05). *** P< 0.001, n≥3 independent preparations. 
(C) Quantification of phospho-tau species as a ratio between the ptau slower mobility upper 
band (upper band ptau)/total tau is shown in the graph. Data are shown as mean ± standard 
deviation.   1.11 ± 0.26 for tau and 3.26 ± 0.59 for tau + AMPKα1-CA. P values were 
calculated by one-way ANOVA. Asterisks indicate significant differences (P<0.05). ** P< 
0.01, n≥3 independent preparations. 
AMPKα1 downregulation destabilizes pathological tau species and changes its 
phosphorylation pattern. 
(D) Extracts of fly heads from flies expressing tau alone and in combination with RNAi 
dAMPKα or AMPKα1-KD, probed with total tau antibody and normalized against actin. 
(E) Quantification of pathological tau species as a ratio between the slower mobility upper 
band/actin is shown in the graph. Data are shown as mean ± standard deviation.   0.90 ± 0.13 
for tau, 0.78 ± 0.05 for tau + RNAi dAMPKα, 0.55 ± 0.06 for tau + AMPKα1-KD. P values 
were calculated by one-way ANOVA. Asterisks indicate significant differences (P<0.05). ** 
P< 0.01, n≥3 independent preparations. 
(F) Extracts of fly heads from flies expressing tau alone and in combination with RNAi 
dAMPKα or AMPKα1-KD, probed with total phospho-tau (p262) antibody and normalised 
against actin. 
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 (G) Quantification of pathological phospho tau species as a ratio between the slower mobility 
upper band/actin is shown in the graph. Data are shown as mean ± standard deviation.   0.99 
± 0.14 for tau, 0.65 ± 0.09 for tau + RNAi dAMPKα, 0.67 ± 0.09 for tau + AMPKα1-KD. P 
values were calculated by one-way ANOVA. Asterisks indicate significant differences 
(P<0.05). * P< 0.05, n≥3 independent preparations. 
  
B
io
lo
gy
 O
pe
n 
• 
A
cc
ep
te
d 
m
an
us
cr
ip
t
  
 
 
B
io
lo
gy
 O
pe
n 
• 
A
cc
ep
te
d 
m
an
us
cr
ip
t
 Figure 6. Modulation of AMPK, autophagy and AMPKα1-CA tau-mediated toxicity.  
Modulation of AMPK and Ref(2)P accumulation in tau flies. 
(A) Western blot analysis of fly head lysates of tau, tau/AMPKα1-KD and tau/AMPKα1-CA 
flies probed with anti-Ref(2)P antibody and normalised for actin. Lysates from tau (control), 
tau/AMPKα1-KD and tau/AMPKα1-CA (experiments) were loaded on the same gel and 
probed on the same membrane.  
(B) Quantification of Ref(2)P accumulation as a ratio between Ref(2)P/actin is shown in the 
graph. Data are shown as mean ± standard deviation.   1.09 ± 0.18 for tau, 2.98 ± 0.48 for 
tau/AMPKα1KD and 0.95 ± 0.57 for tau/AMPKα1-CA. P values were calculated by one-way 
ANOVA. Asterisks indicate significant differences (P<0.05). *** P< 0.001, n≥3 independent 
preparations. 
Rapamycin treatment ameliorates AMPKα1-CA mediated tau phenotype. 
(C) SEM images of the external eye of control (DMSO) and rapamycin treated (Rapamycin) 
flies co-expressing tau and AMPKα1-CA (GMR/+; tau/AMPK CA) under the control of the 
GMR-GAL4 driver. Scale bar in SEM images is equivalent to 100 µm.  
(D) Quantitative analysis of tau-induced toxicity as a distribution of ommatidial distortion 
coefficients (DC) for flies co-expressing tau and AMPKα1-CA (GMR/+; tau/AMPK CA) fed 
with DMSO (black line) and rapamycin (red line).  
The SEM images are representative of the median DC values for each genotype. The 
phenotypes associated with the lower and upper DC values can be seen in supplementary 
figure 7.  DMSO n=9, Rapamycin n=7. Level of significance for a Mann-Whitney directional 
test is ˂0.01. 
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Figure 7. AMPK-mediated tau phosphorylation and autophagy activation: model of 
action. 
Downregulation of AMPK via AMPKα1-KD, although causing a reduction in the activation 
of autophagy, resulted in less tau toxicity, likely due to the reduction of tau phosphorylation 
and hence less toxic tau species. In contrast, overexpression of AMPKα1-CA results in 
increased tau toxicity due to AMPKα1-CA’s ability to phosphorylate tau, thereby promoting 
the appearance of toxic tau species, without affecting autophagy, which would otherwise 
degrade such toxic species. Finally, overexpression of AMPKα1-CA concomitant with 
pharmacological induction of autophagy, via rapamycin, resulted in rescued AMPKα1-CA -
mediated tau toxicity. 
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Supplementary figure 1.
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Immunopreciptation reveals a physical association between tau and AMPKα: control blots.
A. Uncropped blot from Figure 1A. Lysates from HEK293T cells transfected with a pCMV–Flag vector (negative control)
and a pCMV–Flag-tau were immunoprecipitated with ANTI-FLAG M2 Affinity Gel. Immunoprecipitates were analysed by
western blotting, probing against AMPKα. B. Inputs of the identical lysates were analysed by western blotting, probing
against total tau. C. Lysates from HEK293T cells transfected with a pCMV–Flag vector (negative control) and a pCMV–
Flag-tau were immunoprecipitated with anti AMPKα antibody and then incubated with protein A-Sepharose.
Immunoprecipitates were analysed by western blotting, probing against total tau (top). AMPK immunoprecipitation was
validated by probing against AMPKα (bottom).
D. Identical lysates were immunoprecipitated with anti pAMPKα antibody and then incubated with protein A-Sepharose.
Immunoprecipitates were analysed by western blotting, probing against total tau (top). pAMPK immunoprecipitation was
validated by probing against pAMPKα (bottom).
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Degradation of endogenous AMPK via Myc-AMPKα1-KD overexpression in vitro.
A. Extracts from HEK293T overexpressing empty vector or Myc-AMPKα1-KD were used
for detection of AMPKα and normalized with respect to tubulin.
B. Samples were normalized to the tubulin level and the ratio of AMPKα/tubulin is shown
in the graph. Data are shown as mean ± standard deviation. 0.96 ± 0.16 for empty vector,
0.57 ± 0.10 for Myc-AMPKα1-KD. P values were calculated by one-way ANOVA. Asterisks
indicate significant differences (P<0.05). * P< 0.05, n≥3 independent HEK293T
transfections.
Supplementary figure 2.
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Supplementary figure 3.
Transgenic AMPK1α flies validation.
A. Extracts of fly heads from flies expressing tau alone and in
combination with AMPKα1-CA probed with AMPK antibody and
normalized against actin.
B. Extracts of fly heads from flies expressing tau alone and in
combination with RNAi dAMPKα or AMPKα1-KD, probed with AMPK
antibody and normalized against actin.
C. Quantification of dAMPK levels as a ratio between dAMPK/actin is
shown in the graph. Data are shown as mean ± standard deviation.
1.48 ± 0.04 for tau wt; 1.00 ± 0.05 for tau+ RNAi dAMPKα and 1.12
± 0.15 for tau+ AMPKα1-KD.
AMPK
ACTIN ACTIN
40
30
AMPK CA
40
AMPK CA           
Tau                Tau
A.
RNAi AMPK       AMPK KD           
Tau                     Tau                   Tau                         
50
40
80
60
AMPK
ACTIN
AMPK KD
endogenous dAMPK
B.
C.
GM
R 
tau
GM
R 
RN
Ai
 AM
PK
 Ta
u
GM
R A
MP
K-
KD
 Ta
u
0.0
0.5
1.0
1.5
2.0
AMPK  levels
en
do
ge
no
us
 A
M
PK
/A
C
TI
N
Biology Open (2017): doi:10.1242/bio.022863: Supplementary information
B
io
lo
gy
 O
pe
n 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Supplementary figure 4 
GMR/+;tau/+GMR/+ GMR/+; AMPKa1 CA/+ GMR/+; AMPKa1 KD/+
The overexpression of the human AMPKα1-CA and AMPKα1-KD under the control of the GMR driver caused
no appreciable visible external phenotypes.
A. Scanning electron microscope (SEM) images of the external eye of control flies expressing expressing the GMR-
GAL4 driver alone (GMR/+, magenta line) and tau (GMR tau, black line), AMPKα1-CA (GMR/+; AMPKα1-CA/+, blue
line), and AMPKα1-KD (GMR/+; AMPKα1-KD/+, red line) under the control of the GMR-GAL4 driver. Scale bar in SEM
images is equivalent to 100 µm.
B. Quantitative analysis of tau-induced toxicity as distribution of ommatidial distortion coefficients (DC) for control flies
expressing the GMR-GAL4 driver alone (GMR/+, magenta line) and tau (GMR tau, black line), AMPKα1-CA (GMR/+;
AMPKα1-CA/+, blue line), and AMPKα1-KD (GMR/+; AMPKα1-KD/+, red line) under the control of the GMR-GAL4
driver. All the control flies displays a fully wild type eye phenotype.
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The range of ommatidial distortion coefficients (DC) of flies in
Figure 3.
Tau flies had a DC range that was 0.31 - 0.54, values that were
higher than those of the GMR tau RNAi dAMPKα flies (0.26 -
0.42). DC values for the phenotypes at the lower and upper
extremes of the distribution range are shown on each image. Scale
bar in SEM images is equivalent to 100 µm.
Supplementary figure 5. 
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The range of ommatidial distortion coefficients (DC) of flies in Figure 4.
Tau flies had a DC range that was 0.31 - 0.50. Co-expression of AMPK CA with tau gave
a range of 0.37 - 0.64 indicating a more severe phenotype, while Co-expression of
AMPK KD with tau gave a range of 0.30 - 0.36 indicating a less severe phenotype. DC
values for the phenotypes at the lower and upper extremes of the distribution range are
shown on each image. Scale bar in SEM images is equivalent to 100 µm.
Supplementary figure 6. 
Biology Open (2017): doi:10.1242/bio.022863: Supplementary information
B
io
lo
gy
 O
pe
n 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Lowest DC
Highest DC
DMSO                                      
DC = 0.78 
Rapamycin
DC = 0.36      
Rapamycin
DC = 0.66 
The range of ommatidial distortion coefficients (DC) of flies in
Figure 8
DMSO treated flies had a DC range that was 0.45 - 0.78, values
that were higher than those of the rapamycin treated flies (0.36 -
0.66). DC values for the phenotypes at the lower and upper
extremes of the distribution range are shown on each image. Scale
bar in SEM images is equivalent to 100 µm.
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